JPS59500115A - 生物液体の分析 - Google Patents
生物液体の分析Info
- Publication number
- JPS59500115A JPS59500115A JP58500939A JP50093983A JPS59500115A JP S59500115 A JPS59500115 A JP S59500115A JP 58500939 A JP58500939 A JP 58500939A JP 50093983 A JP50093983 A JP 50093983A JP S59500115 A JPS59500115 A JP S59500115A
- Authority
- JP
- Japan
- Prior art keywords
- phosphatidylglycerol
- phospholipids
- cholesterol
- amniotic fluid
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013060 biological fluid Substances 0.000 title claims description 22
- 238000004458 analytical method Methods 0.000 title description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 32
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 31
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 30
- 150000003904 phospholipids Chemical class 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000003153 chemical reaction reagent Substances 0.000 claims description 25
- 235000012000 cholesterol Nutrition 0.000 claims description 25
- 210000004381 amniotic fluid Anatomy 0.000 claims description 23
- 239000000872 buffer Substances 0.000 claims description 14
- -1 alkyltrimethylammonium halides Chemical class 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 210000000991 chicken egg Anatomy 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 7
- 230000004520 agglutination Effects 0.000 claims description 6
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 5
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 230000003139 buffering effect Effects 0.000 claims description 4
- 239000002131 composite material Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 125000001095 phosphatidyl group Chemical group 0.000 claims description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- 150000004820 halides Chemical group 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims 3
- 230000002776 aggregation Effects 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000012062 aqueous buffer Substances 0.000 claims 2
- 230000026030 halogenation Effects 0.000 claims 1
- 238000005658 halogenation reaction Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 239000000243 solution Substances 0.000 description 22
- 239000000787 lecithin Substances 0.000 description 15
- 229940067606 lecithin Drugs 0.000 description 15
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 14
- 235000010445 lecithin Nutrition 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 239000012064 sodium phosphate buffer Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 235000013345 egg yolk Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- IPIGTJPBWJEROO-UHFFFAOYSA-B thorium(4+);tetraphosphate Chemical compound [Th+4].[Th+4].[Th+4].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O IPIGTJPBWJEROO-UHFFFAOYSA-B 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000012754 cardiac puncture Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- BIIWAHJQGWZQQA-RTFZCPRASA-M (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol;hexadecyl(trimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C.C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BIIWAHJQGWZQQA-RTFZCPRASA-M 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- OGBOARUVIUNZDI-UHFFFAOYSA-N 1-bromohexadecane;n,n-dimethylmethanamine Chemical compound CN(C)C.CCCCCCCCCCCCCCCCBr OGBOARUVIUNZDI-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 238000005298 biophysical measurement Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 210000001006 meconium Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- HNJXPTMEWIVQQM-UHFFFAOYSA-M triethyl(hexadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](CC)(CC)CC HNJXPTMEWIVQQM-UHFFFAOYSA-M 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/344,930 US4388412A (en) | 1982-02-02 | 1982-02-02 | Immunoassay of phospholipid, such as phosphatidylcholine, in fluids such as amniotic |
| US344930 | 1982-02-02 | ||
| US426614 | 1995-04-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59500115A true JPS59500115A (ja) | 1984-01-19 |
| JPH0445784B2 JPH0445784B2 (OSRAM) | 1992-07-27 |
Family
ID=23352719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58500939A Granted JPS59500115A (ja) | 1982-02-02 | 1983-01-28 | 生物液体の分析 |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US4388412A (OSRAM) |
| JP (1) | JPS59500115A (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4537718A (en) * | 1982-10-26 | 1985-08-27 | Columbia University In The City Of New York | Impermeant spectroscopic probes |
| US4784961A (en) * | 1987-03-23 | 1988-11-15 | Abbott Laboratories | Fluorescence polarization method for monitoring fetal lung maturity |
| US5223627A (en) * | 1986-07-15 | 1993-06-29 | Abbott Laboratories | Fluorescence polarization method for monitoring fetal lung maturity |
| US5010016A (en) * | 1989-08-09 | 1991-04-23 | Sbarra Anthony J | Method and test kit for the determination of fetal pulmonary maturity status |
| US5227308A (en) * | 1991-11-05 | 1993-07-13 | University Of Hawaii | Method for assessing lung maturity using fluorescence from naphthalene-based probes |
| FI112825B (fi) * | 2001-07-11 | 2004-01-15 | Antti Nissinen | Menetelmä alkoholinkulutuksen osoittamiseksi, menetelmässä käytettäviä välineitä sekä niiden valmistus |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE390T1 (de) * | 1978-11-01 | 1981-11-15 | Contraves Ag | Verfahren zur verminderung der stoerung einer photometrischen messung durch lichtstreuung in einer zu messenden suspension und reagenz zur durchfuehrung des verfahrens. |
| US4233032A (en) * | 1979-02-12 | 1980-11-11 | University Of North Carolina At Chapel Hill | Fetal lung maturity test |
| US4257771A (en) * | 1979-04-30 | 1981-03-24 | Hugh Yee | Process for measuring lecithin concentration in biological fluids |
| US4292041A (en) * | 1979-11-02 | 1981-09-29 | Merck & Co., Inc. | Surfactant assay |
-
1982
- 1982-02-02 US US06/344,930 patent/US4388412A/en not_active Expired - Lifetime
-
1983
- 1983-01-28 JP JP58500939A patent/JPS59500115A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| US4388412A (en) | 1983-06-14 |
| JPH0445784B2 (OSRAM) | 1992-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0064274B1 (en) | Method for assaying antigen-antibody reactions and reagent therefor | |
| US4292038A (en) | Formamide-containing latex agglutinating reagent for immunoassay | |
| US20160327555A1 (en) | Method for avoiding influence of endogenous lipoprotein and reagent | |
| JPS59500115A (ja) | 生物液体の分析 | |
| EP0379133B1 (de) | Verwendung von zweiwertigen Kationen in immunchemischen Tests | |
| US4459362A (en) | Immunoassay of phospholipid, such as phosphatidyl choline, in fluids such as amniotic | |
| EP0064275B1 (en) | Immunochemical reagent | |
| US20020090638A1 (en) | Stabilization of particles and reduction of sample discordance in immunoassays using casein coating of particles | |
| Yamamoto et al. | Anti‐Phospholipid Antibodies in Preeclampsia and Their Binding Ability for Placental Villous Lipid Fractions | |
| US4321058A (en) | Latex composition and method for determining erythropoietin | |
| US20190331680A1 (en) | Method for stabilizing glycerophospholipids and reagents using same | |
| WO2007066731A1 (ja) | 抗リン脂質抗体測定試薬及び抗トレポネーマ・パリダム抗体測定試薬 | |
| JP3290520B2 (ja) | 抗リン脂質抗体測定法 | |
| JPH07103981A (ja) | 抗リン脂質抗体測定法 | |
| JPH11295312A (ja) | 抗リン脂質抗体測定方法及び抗リン脂質抗体測定用免疫凝集反応試薬 | |
| JP2001228154A (ja) | 分析方法と凝集反応試薬 | |
| Cohen | A hemolytic Serologic réaction without complement as a possible test for syphilis | |
| HASEGAWA et al. | Detection of serum antibodies to amino-pyrine or its derivatives by a passive hemagglutination assay method | |
| Albanese et al. | Analysis of alpha-fetoprotein by a procedure combining crossed immunoaffinoelectrophoresis and immunoblotting | |
| JPH0587810A (ja) | 担体無機粒子の保存方法 | |
| JPH02231566A (ja) | 酵素標識レセプター組成物、診断キット、およびリガンド測定法への利用 | |
| JPWO1989002075A1 (ja) | ヒトの肺表面活性物質の測定方法 |